Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRBU 
Caribou Biosciences Inc (CRBU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: CRBU (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.12
1 Year Target Price $11.12
| 5 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.99% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.33M USD | Price to earnings Ratio - | 1Y Target Price 11.12 |
Price to earnings Ratio - | 1Y Target Price 11.12 | ||
Volume (30-day avg) 9 | Beta 2.59 | 52 Weeks Range 0.66 - 3.54 | Updated Date 11/30/2025 |
52 Weeks Range 0.66 - 3.54 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.35 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -1337.58% |
Management Effectiveness
Return on Assets (TTM) -32.41% | Return on Equity (TTM) -74.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 59532993 | Price to Sales(TTM) 19.51 |
Enterprise Value 59532993 | Price to Sales(TTM) 19.51 | ||
Enterprise Value to Revenue 6.4 | Enterprise Value to EBITDA -36.94 | Shares Outstanding 93468038 | Shares Floating 84428744 |
Shares Outstanding 93468038 | Shares Floating 84428744 | ||
Percent Insiders 9.78 | Percent Institutions 39.02 |
Upturn AI SWOT
Caribou Biosciences Inc
Company Overview
History and Background
Caribou Biosciences Inc. was founded in 2011 based on CRISPR technology licensed from UC Berkeley. It focuses on developing allogeneic cell therapies for cancer and other diseases. The company has evolved from early-stage research to clinical trials.
Core Business Areas
- Allogeneic Cell Therapies: Caribou is developing off-the-shelf cell therapies using its Cas12a CRISPR hybrid RNA-DNA (chRDNA) technology to engineer immune cells, primarily CAR-T and CAR-NK cells, to target cancer. Its lead product candidate is CB-010.
Leadership and Structure
Rachel Haurwitz serves as President and CEO. The company has a board of directors and operates with a typical structure for a publicly traded biotechnology company.
Top Products and Market Share
Key Offerings
- CB-010: CB-010 is an allogeneic anti-CD19 CAR-T cell therapy in Phase 1 clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Market share is currently non-existent as product is still in clinical trials. Competitors in this space are CRISPR Therapeutics (CRSP) and Allogene Therapeutics (ALLO).
- CB-011: CB-011 is an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma (r/r MM) in Phase 1 clinical trials. Market share is currently non-existent as product is still in clinical trials. Competitors are CRISPR Therapeutics (CRSP) and Allogene Therapeutics (ALLO).
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, driven by advancements in gene editing and immunotherapy. There is increasing demand for off-the-shelf allogeneic cell therapies as an alternative to autologous therapies.
Positioning
Caribou positions itself as a leader in CRISPR-edited allogeneic cell therapies, emphasizing its chRDNA technology for improved precision and durability. They face competition from other companies developing similar therapies.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is estimated to be in the tens of billions of dollars annually. Caribou is positioned to capture a portion of this market with successful clinical development and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary chRDNA CRISPR technology
- Strong scientific founding and expertise
- Promising early clinical data for CB-010 and CB-011
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Dependence on clinical trial success
Opportunities
- Potential for partnerships and collaborations
- Expansion of pipeline to other cancer targets
- Advancements in cell therapy manufacturing
Threats
- Competition from other gene editing and cell therapy companies
- Regulatory hurdles and approval timelines
- Clinical trial failures
Competitors and Market Share
Key Competitors
- CRSP
- ALLO
- BEAM
Competitive Landscape
Caribou has a strong technology platform with clinical trials that are currently in Phase 1. CRISPR (CRSP) currently has the leading products with more advanced stages of clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and preclinical/clinical milestones.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its cell therapies.
Recent Initiatives: Recent initiatives include advancing CB-010 and CB-011 in clinical trials, expanding its pipeline with new targets, and optimizing manufacturing processes.
Summary
Caribou Biosciences has a promising technology platform with its allogeneic cell therapy programs. The company's success hinges on positive clinical trial outcomes and regulatory approvals. They face significant competition from established gene editing companies, and have a limited cash runway that could be a concern in the future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Caribou Biosciences Inc. website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise. Financial data relies on sources and could be out of date. Please do your own research before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Caribou Biosciences Inc
Exchange NASDAQ | Headquaters Berkeley, CA, United States | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO, President & Director Dr. Rachel E. Haurwitz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 147 | Website https://cariboubio.com |
Full time employees 147 | Website https://cariboubio.com | ||
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.